Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;58(4):327.
doi: 10.4103/0019-5154.113968.

Aminolevulinic Acid-photodynamic therapy of Basal cell carcinoma and factors affecting the response to treatment: a clinical trial

Zohreh Tehranchinia  1 , Hoda Rahimi, Mahsa Seyed Ahadi, Maral Seyed Ahadi
Affiliations

Aminolevulinic Acid-photodynamic therapy of Basal cell carcinoma and factors affecting the response to treatment: a clinical trial

Zohreh Tehranchinia et al. Indian J Dermatol. 2013 Jul.

Abstract

Background: Basal cell carcinoma (BCC) is the most common type of skin cancer in humans. Photodynamic therapy (PDT) is a non-invasive therapeutic modality that may be considered as a valuable treatment option for BCC. This study was designed with the aim of evaluating the efficacy of PDT in treatment of BCC and factors that may affect the response rate.

Materials and methods: This clinical trial was conducted on 12 patients (28 BCC lesions) who were treated with aminulevulinic acid (ALA)-PDT, monthly, up to 6 sessions and the clinical response, cosmetic results, and possible side effects were evaluated.

Results: The study was performed on 28 BCC lesions from 12 patients. Complete response was achieved in 9 (32.1%) lesions. Complete response rate was higher in younger patients (P < 0.01) and those with smaller lesions (P < 0.001). Superficial type also had significant higher response rate (P < 0.05). Patients with history of radiotherapy for the treatment of tinea capitis in childhood showed less response (P < 0.05). Cosmetic results were excellent or good in 77.5% cases. After 6 months of follow-up, none of the resolved lesions recurred.

Conclusion: PDT would be a good therapeutic option in treatment of BCC with acceptable efficacy and low side effects. Younger patients, superficial BCCs, and smaller lesions show better response to ALA-PDT. History of radiotherapy may be associated with a lower response rate.

Keywords: Aminolevulinic acid; basal cell carcinoma; non-melanocytic skin cancer; photodynamic therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

Figures

Diagram 1
Diagram 1
Treatment protocol of ALA-PDT for BCC according to clinical response
Figure 1
Figure 1
Basal cell carcinoma of scalp. (a) Before photodynamic therapy, (b) with complete response after photodynamic therapy
Figure 2
Figure 2
Pigmented BCC of scalp. (a) Before photodynamic therapy, (b) With partial response after photodynamic therapy
See this image and copyright information in PMC

References

    1. Kuijpers DI, Thissen MR, Neumann MH. Basal cell carcinoma: Treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol. 2002;3:247–59. - PubMed
    1. Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V, et al. Photodynamic therapy using topical methyl aminolevulinatevs surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140:17–23. - PubMed
    1. Tierney E, Barker A, Ahdout J, Hanke CW, Moy RL, Kouba DJ. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg. 2009;35:725–46. - PubMed
    1. Kaviani A, Ataie-Fashtami L, Fateh M, Sheikhbahaee N, Ghodsi M, Zand N, et al. Photodynamic therapy of head and neck basal cell carcinoma according to different clinicopathologic features. Lasers Surg Med. 2005;36:377–82. - PubMed
    1. Hallaji Z, Rahimi H, Mirshams-Shahshahani M. Comparison of risk factors of single Basal cell carcinoma with multiple Basal cell carcinomas. Indian J Dermatol. 2011;56:398–402. - PMC - PubMed

LinkOut - more resources